Literature DB >> 3443647

Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells.

L Lennard1.   

Abstract

A highly sensitive reversed-phase high-performance liquid chromatographic assay, with ultraviolet detection, for 6-thioinosinic acid and the 6-thioguanine nucleotides (6TGNs) was developed. The 6TGNs are major red blood cell metabolites of the immunosuppressive agent azathioprine and the cytotoxic drugs 6-thioguanine and 6-mercaptopurine. The assay is based on the specific extraction, via phenyl mercury adduct formation, of the thiopurine released on acid hydrolysis of the thionucleotide metabolite. Red blood cell 6TGN concentrations in eighteen leukaemic children receiving chronic 6-mercaptopurine chemotherapy were measured and compared to a previously published spectrophotofluorometric assay. Linear regression analysis gave r = 0.991; P less than 0.001; y = 40 + 0.94x.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443647     DOI: 10.1016/0378-4347(87)80340-7

Source DB:  PubMed          Journal:  J Chromatogr


  13 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice.

Authors:  V Kurowski; H Iven
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity.

Authors:  Fang Li; Brooke L Fridley; Alice Matimba; Krishna R Kalari; Linda Pelleymounter; Irene Moon; Yuan Ji; Gregory D Jenkins; Anthony Batzler; Liewei Wang; Richard M Weinshilboum
Journal:  Drug Metab Dispos       Date:  2010-09-20       Impact factor: 3.922

5.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors:  P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

6.  Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia.

Authors:  B M de Oliveira; M B Viana; C L Zani; A J Romanha
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

7.  Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.

Authors:  G Stocco; M H Cheok; K R Crews; T Dervieux; D French; D Pei; W Yang; C Cheng; C-H Pui; M V Relling; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

8.  Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Authors:  E Jacqz-Aigrain; E Bessa; Y Medard; Y Mircheva; E Vilmer
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

9.  Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia.

Authors:  L Lennard; J P Hale; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

Review 10.  Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review.

Authors:  A Anstey; L Lennard; S C Mayou; J D Kirby
Journal:  J R Soc Med       Date:  1992-12       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.